AstraZeneca_NNP Annual_JJ Report_NNP and_CC Form_NN 20-F_JJ 2002_CD Additional_JJ Information_NN for_IN US_NNP Investors_NNPS www_NN ._.
com_NN 113_CD Additional_JJ Information_NN for_IN US_NNP Investors_NNPS Differences_NNS between_IN UK_NNP and_CC US_NNP 2002_CD ,_, under_IN US_NNP GAAP_NNP ,_, goodwill_NN was_VBD required_VBN Pension_NN and_CC post-retirement_NN benefits_NNS accounting_VBG principles_NNS to_TO be_VB capitalized_VBN and_CC amortised_VBN ._.
Now_RB ,_, instead_RB There_EX are_VBP four_CD main_JJ differences_NNS between_IN of_IN being_VBG amortised_VBN ,_, goodwill_NN is_VBZ tested_VBN current_JJ UK_NNP GAAP_NNP and_CC US_NNP GAAP_NNP in_IN The_DT accompanying_VBG consolidated_JJ financial_JJ annually_RB for_IN impairment_NN ._.
Amortisation_NNP accounting_NN for_IN pension_NN costs_NNS :_: statements_NNS included_VBD in_IN this_DT Annual_JJ Report_NNP are_VBP charged_VBN under_IN UK_NNP GAAP_NNP is_VBZ added_VBN back_RB in_IN prepared_JJ in_IN accordance_NN with_IN UK_NNP GAAP_NNP ._.
the_DT reconciliation_NN of_IN net_JJ income_NN ._.
The_DT i_FW US_PRP GAAP_NNP requires_VBZ measurements_NNS of_IN plan_NN Certain_NNP significant_JJ differences_NNS between_IN UK_NNP intangible_JJ recognized_VBN as_IN assembled_VBN assets_NNS and_CC obligations_NNS to_TO be_VB made_VBN as_IN at_IN GAAP_NNP and_CC US_NNP GAAP_NNP which_WDT affect_VBP workforce_NN has_VBZ been_VBN reclassified_VBN as_IN goodwill_NN ._.
the_DT date_NN of_IN the_DT financial_JJ statements_NNS or_CC a_DT AstraZenecas_NNP net_JJ income_NN and_CC shareholders_NNS date_NN not_RB more_RBR than_IN three_CD months_NNS prior_RB to_TO equity_NN are_VBP set_VBN out_RP below_IN ._.
Identifiable_JJ intangible_JJ assets_NNS ,_, which_WDT principally_RB that_IN date_NN ._.
Under_IN UK_NNP GAAP_NNP ,_, calculations_NNS include_VBP patents_NNS ,_, know-how_NN and_CC product_NN may_MD be_VB based_VBN on_IN the_DT results_NNS of_IN the_DT latest_JJS Purchase_NN accounting_NN adjustments_NNS registrations_NNS ,_, are_VBP amortised_VBN over_IN their_PRP$ actuarial_JJ valuation_NN :_: Under_IN UK_NNP GAAP_NNP the_DT merger_NN of_IN Astra_NNP and_CC estimated_VBN useful_JJ lives_NNS which_WDT vary_VBP between_IN 5_CD Zeneca_NNP was_VBD accounted_VBN for_IN as_IN a_DT merger_NN of_IN years_NNS and_CC 20_CD years_NNS with_IN a_DT weighted_JJ average_JJ ii_NN US_NNP GAAP_NNP mandates_VBZ a_DT particular_JJ actuarial_JJ equals_VBZ pooling-of-interests_NNS ._.
Under_IN US_NNP life_NN of_IN approximately_RB 13_CD years_NNS ._.
method_NN the_DT projected_VBN unit_NN credit_NN GAAP_NNP the_DT merger_NN was_VBD accounted_VBN for_IN as_IN the_DT method_NN and_CC requires_VBZ that_IN each_DT acquisition_NN of_IN Astra_NNP by_IN Zeneca_NNP using_VBG At_IN 31_CD December_NNP 2002_CD and_CC 2001_CD ,_, significant_JJ assumption_NN necessary_JJ to_TO purchase_VB accounting_NN ._.
Under_IN purchase_NN shareholders_NNS equity_NN includes_VBZ capitalized_JJ determine_VB annual_JJ pension_NN cost_NN reflects_VBZ accounting_NN ,_, the_DT cost_NN of_IN the_DT investment_NN is_VBZ goodwill_NN of_IN $_$ 13,600_CD m_NN and_CC $_$ 12,169_CD m_NN best_JJS estimates_NNS solely_RB with_IN regard_NN to_TO that_DT calculated_VBN at_IN the_DT market_NN value_NN of_IN the_DT shares_NNS respectively_RB net_JJ of_IN amortisation_NN and_CC individual_JJ assumption_NN ._.
UK_NNP GAAP_NNP does_VBZ issued_VBN together_RB with_IN other_JJ incidental_JJ costs_NNS impairment_NN of_IN $_$ 2,383_CD m_NN and_CC $_$ 2,180_CD m_NN and_CC not_RB mandate_VB a_DT particular_JJ method_NN ,_, but_CC and_CC the_DT assets_NNS and_CC liabilities_NNS of_IN the_DT acquired_VBN capitalized_JJ identifiable_JJ intangible_JJ assets_NNS of_IN requires_VBZ that_IN the_DT method_NN and_CC entity_NN are_VBP recorded_VBN at_IN fair_JJ value_NN ._.
As_IN a_DT result_NN of_IN $_$ 9,433_CD m_NN and_CC $_$ 9,789_CD m_NN respectively_RB net_JJ of_IN assumptions_NNS taken_VBN as_IN a_DT whole_JJ should_MD be_VB the_DT fair_JJ value_NN exercise_NN ,_, increases_NNS in_IN the_DT values_NNS amortisation_NN and_CC impairment_NN of_IN $_$ 4,566_CD m_NN and_CC compatible_JJ and_CC lead_JJ to_TO the_DT actuarys_NNS best_JJS of_IN Astras_NNP tangible_JJ fixed_VBN assets_NNS and_CC inventory_NN $_$ 3,475_CD m._FW Goodwill_NNP on_IN businesses_NNS disposed_VBN estimate_NN of_IN the_DT cost_NN of_IN providing_VBG the_DT were_VBD recognized_VBN and_CC values_VBZ attributed_VBN to_TO their_PRP$ of_IN is_VBZ charged_VBN to_TO the_DT gain_NN or_CC loss_NN on_IN disposal_NN ._.
benefits_NNS promised_VBD :_: in-process_JJ research_NN and_CC development_NN ,_, existing_VBG products_NNS and_CC assembled_VBD work_NN force_NN ,_, On_IN disposal_NN of_IN a_DT business_NN ,_, the_DT gain_NN or_CC loss_NN iii_NN under_IN US_NNP GAAP_NNP ,_, a_DT negative_JJ pension_NN cost_NN together_RB with_IN appropriate_JJ deferred_VBN taxation_NN under_IN US_NNP GAAP_NNP may_MD differ_VB from_IN that_DT under_IN may_MD arise_VB where_WRB a_DT significant_JJ effects_NNS ._.
The_DT difference_NN between_IN the_DT cost_NN of_IN UK_NNP GAAP_NNP due_JJ principally_RB to_TO goodwill_NN unrecognised_JJ net_JJ asset_NN or_CC gain_NN exists_VBZ at_IN investment_NN and_CC the_DT fair_JJ value_NN of_IN the_DT assets_NNS capitalized_VBN and_CC amortised_VBN ,_, together_RB with_IN the_DT the_DT time_NN of_IN implementation_NN ._.
This_DT is_VBZ and_CC liabilities_NNS of_IN Astra_NNP was_VBD recorded_VBN as_IN appropriate_JJ share_NN of_IN other_JJ differences_NNS required_VBN to_TO be_VB amortised_VBN on_IN a_DT straight-line_JJ goodwill_NN ._.
The_DT amount_NN allocated_VBN to_TO in-process_JJ between_IN UK_NNP and_CC US_NNP accounting_NN principles_NNS basis_NN over_IN the_DT average_JJ remaining_VBG service_NN research_NN and_CC development_NN was_VBD ,_, as_IN required_VBN recognized_VBN previously_RB ._.
Under_IN UK_NNP GAAP_NNP ,_, by_IN US_NNP GAAP_NNP ,_, expensed_VBD immediately_RB in_IN the_DT AstraZenecas_NNPS policy_NN is_VBZ not_RB to_TO recognize_VB first_JJ reporting_NN period_NN after_IN the_DT business_NN Capitalisation_NNP of_IN interest_NN pension_NN credits_NNS in_IN its_PRP$ financial_JJ statements_NNS combination_NN ._.
Fair_NNP value_NN adjustments_NNS to_TO the_DT AstraZeneca_NNP does_VBZ not_RB capitalize_VB interest_NN in_IN its_PRP$ unless_IN a_DT refund_NN of_IN ,_, or_CC reduction_NN in_IN ,_, recorded_VBN amount_NN of_IN inventory_NN were_VBD expensed_VBN financial_JJ statements_NNS ._.
US_NNP GAAP_NNP requires_VBZ contributions_NNS is_VBZ likely_JJ :_: and_CC in_IN the_DT period_NN the_DT inventory_NN was_VBD utilised_VBN ._.
interest_NN incurred_VBN as_IN part_NN of_IN the_DT cost_NN of_IN Additional_JJ amortisation_NN and_CC depreciation_NN have_VBP constructing_VBG fixed_VBN assets_NNS to_TO be_VB capitalized_VBN iv_NN under_IN US_NNP GAAP_NNP ,_, a_DT minimum_JJ pension_NN also_RB been_VBN recorded_VBN in_IN respect_NN of_IN the_DT fair_JJ value_NN and_CC amortised_VBN over_IN the_DT life_NN of_IN the_DT asset_NN ._.
liability_NN is_VBZ recognized_VBN through_IN other_JJ adjustments_NNS to_TO tangible_JJ and_CC intangible_JJ assets_NNS comprehensive_JJ income_NN in_IN certain_JJ and_CC the_DT resulting_VBG goodwill_NN ._.
Dividends_NNS circumstances_NNS when_WRB there_EX is_VBZ a_DT deficit_NN of_IN Under_IN UK_NNP GAAP_NNP Ordinary_NNP Share_NNP dividends_NNS plan_VBP assets_NNS relative_JJ to_TO the_DT projected_VBN In_IN the_DT consolidated_JJ financial_JJ statements_NNS proposed_VBN are_VBP provided_VBN for_IN in_IN the_DT year_NN in_IN benefits_NNS obligation_NN ._.
Under_IN UK_NNP GAAP_NNP ,_, prepared_VBN under_IN UK_NNP GAAP_NNP ,_, goodwill_NN arising_VBG on_IN respect_NN of_IN which_WDT they_PRP are_VBP recommended_VBN by_IN there_EX is_VBZ no_DT such_JJ requirement_NN ._.
acquisitions_NNS made_VBD prior_RB to_TO 1_CD January_NNP 1998_CD the_DT Board_NNP of_IN Directors_NNS for_IN approval_NN by_IN the_DT accounted_VBN for_IN under_IN the_DT purchase_NN method_NN shareholders_NNS ._.
Under_IN US_NNP GAAP_NNP such_JJ has_VBZ been_VBN eliminated_VBN against_IN shareholders_NNS dividends_NNS are_VBP not_RB provided_VBN for_IN until_IN declared_VBN equity_NN ._.
Under_IN the_DT requirements_NNS of_IN UK_NNP by_IN the_DT Board_NNP ._.
Financial_NNP Reporting_NNP Standard_NNP 10_CD Goodwill_NNP and_CC Intangible_NNP Assets_NNPS ,_, goodwill_NN on_IN Deferred_JJ taxation_NN acquisitions_NNS made_VBN after_IN 1_CD January_NNP 1998_CD is_VBZ Deferred_JJ taxation_NN is_VBZ provided_VBN on_IN a_DT full_JJ liability_NN capitalized_VBN and_CC amortised_VBN over_IN its_PRP$ estimated_VBN basis_NN under_IN US_NNP GAAP_NNP ,_, which_WDT permits_VBZ useful_JJ life_NN which_WDT is_VBZ generally_RB presumed_VBN not_RB to_TO deferred_VBN tax_NN assets_NNS to_TO be_VB recognized_VBN if_IN their_PRP$ exceed_VBP 20_CD years_NNS ._.
UK_NNP GAAP_NNP requires_VBZ that_IN on_IN realisation_NN is_VBZ considered_VBN to_TO be_VB more_RBR likely_JJ than_IN subsequent_JJ disposal_NN or_CC termination_NN of_IN a_DT not_RB ._.
Under_IN current_JJ UK_NNP GAAP_NNP ,_, full_JJ provision_NN is_VBZ previously_RB acquired_VBN business_NN ,_, any_DT goodwill_NN also_RB made_VBD although_IN there_EX are_VBP a_DT number_NN of_IN previously_RB taken_VBN directly_RB to_TO shareholders_NNS different_JJ bases_NNS on_IN which_WDT this_DT calculation_NN is_VBZ equity_NN is_VBZ then_RB charged_VBN in_IN the_DT income_NN made_VBN ,_, eg_NN rolled_VBD over_IN capital_NN gains_NNS ._.
statement_NN against_IN the_DT profit_NN or_CC loss_NN on_IN disposal_NN or_CC termination_NN ._.
Up_IN until_IN 1_CD January_NNP AstraZeneca_NNP Annual_JJ Report_NNP and_CC Form_NN 20-F_JJ 2002_CD Additional_JJ Information_NN for_IN US_NNP Investors_NNPS www_NN ._.
com_NN 114_CD Additional_JJ Information_NN for_IN US_NNP Investors_NNPS continued_VBD Differences_NNS between_IN UK_NNP and_CC US_NNP the_DT income_NN statement_NN in_IN subsequent_JJ periods_NNS comprise_VBP current_JJ asset_NN investments_NNS held_VBD as_IN accounting_NN principles_NNS continued_VBD until_IN all_DT disposal_NN obligations_NNS and_CC readily_RB disposable_JJ stores_NNS of_IN value_NN ._.
Under_IN commitments_NNS have_VBP been_VBN completed_VBN ._.
95_CD cash_NN equivalents_NNS ,_, comprising_VBG Restructuring_NN costs_NNS short_JJ term_NN highly_RB liquid_JJ investments_NNS ,_, generally_RB Under_IN UK_NNP GAAP_NNP ,_, provisions_NNS are_VBP made_VBN for_IN Current_JJ assets_NNS and_CC liabilities_NNS with_IN original_JJ maturities_NNS of_IN three_CD months_NNS or_CC less_JJR ,_, restructuring_VBG costs_NNS once_RB a_DT detailed_JJ formal_JJ In_IN the_DT Groups_NNS financial_JJ statements_NNS prepared_VBN are_VBP grouped_VBN together_RB with_IN cash_NN :_: short_JJ term_NN plan_NN is_VBZ in_IN place_NN and_CC valid_JJ expectations_NNS have_VBP under_IN UK_NNP GAAP_NNP ,_, no_DT cost_NN is_VBZ accrued_VBN for_IN the_DT borrowings_NNS repayable_JJ on_IN demand_NN would_MD not_RB been_VBN raised_VBN in_IN those_DT affected_VBN that_IN the_DT share_NN options_NNS awarded_VBN to_TO employees_NNS under_IN be_VB included_VBN within_IN cash_NN and_CC cash_NN equivalents_NNS restructuring_VBG will_MD be_VB carried_VBN out_RP ._.
US_NNP GAAP_NNP the_DT Zeneca_NNP 1994_CD Executive_NNP Share_NNP Option_NN and_CC movements_NNS on_IN those_DT borrowings_NNS would_MD requires_VBZ a_DT number_NN of_IN specific_JJ criteria_NNS to_TO be_VB Scheme_NNP ,_, the_DT AstraZeneca_NNP Share_NN Option_NN be_VB included_VBN in_IN financing_NN activities_NNS ._.
met_VBN before_IN such_JJ costs_NNS can_MD be_VB recognized_VBN as_IN Plan_NNP ,_, and_CC the_DT AstraZeneca_NNP Savings-Related_NNP an_DT expense_NN ._.
Among_IN these_DT are_VBP the_DT Share_NN Option_NN Scheme_NN as_IN the_DT exercise_NN price_NN is_VBZ New_JJ accounting_NN standards_NNS adopted_VBN requirements_NNS that_IN the_DT costs_NNS incurred_VBN are_VBP equivalent_JJ to_TO the_DT market_NN value_NN at_IN the_DT date_NN of_IN Statement_NN of_IN Financial_NNP Accounting_NNP Standards_NNPS incremental_JJ to_TO other_JJ costs_NNS incurred_VBN by_IN the_DT grant_NN ._.
Under_IN US_NNP GAAP_NNP the_DT cost_NN is_VBZ calculated_VBN SFAS_NNP No._NN ._.
141_CD Business_NN Combinations_NNS and_CC company_NN ,_, or_CC represent_VB amounts_NNS to_TO be_VB as_IN the_DT difference_NN between_IN the_DT option_NN price_NN SFAS_NNP No._NN ._.
142_CD Goodwill_NNP and_CC Other_JJ Intangible_JJ incurred_VBN under_IN contractual_JJ obligations_NNS which_WDT and_CC the_DT market_NN price_NN at_IN the_DT date_NN of_IN grant_NN or_CC ,_, Assets_NNS were_VBD issued_VBN in_IN July_NNP 2001_CD and_CC are_VBP are_VBP not_RB associated_VBN with_IN or_CC do_VB not_RB benefit_VB for_IN variable_JJ plans_NNS ,_, at_IN the_DT end_NN of_IN the_DT reporting_NN effective_JJ for_IN accounting_NN periods_NNS commencing_VBG activities_NNS that_WDT will_MD be_VB continued_VBN ._.
Also_RB ,_, all_DT period_NN until_IN measurement_NN date_NN ._.
Under_IN the_DT on_IN or_CC after_IN 15_CD December_NNP 2001_CD ._.
Under_IN SFAS_NNP significant_JJ actions_NNS arising_VBG from_IN a_DT restructuring_NN requirements_NNS of_IN APB_NNP Opinion_NNP No._NN ._.
141_CD ,_, all_DT business_NN combinations_NNS initiated_VBN and_CC their_PRP$ completion_NN dates_NNS must_MD be_VB identified_VBN compensation_NN cost_NN would_MD be_VB amortised_VBN over_IN after_IN 30_CD June_NNP 2001_CD must_MD be_VB accounted_VBN for_IN by_IN the_DT balance_NN sheet_NN date_NN ._.
To_TO the_DT extent_NN that_IN the_DT period_NN from_IN the_DT date_NN the_DT options_NNS are_VBP using_VBG the_DT purchase_NN method_NN ._.
The_DT pooling_VBG of_IN restructuring_NN costs_NNS are_VBP related_VBN to_TO the_DT activities_NNS granted_VBN to_TO the_DT date_NN they_PRP are_VBP first_JJ exercisable_JJ ._.
interest_NN method_NN is_VBZ no_RB longer_RB permitted_VBN ._.
of_IN the_DT acquired_VBN company_NN ,_, US_NNP GAAP_NNP allows_VBZ Under_IN US_NNP GAAP_NNP in_IN the_DT net_JJ income_NN Intangible_JJ assets_NNS arising_VBG on_IN acquisitions_NNS are_VBP them_PRP to_TO be_VB recognized_VBN as_IN a_DT liability_NN upon_IN reconciliation_NN ,_, the_DT Group_NNP has_VBZ adjusted_VBN for_IN required_VBN to_TO be_VB amortised_VBN to_TO residual_JJ values_NNS acquisition_NN ._.
stock_NN compensation_NN costs_NNS and_CC calculated_VBN over_IN their_PRP$ estimated_VBN useful_JJ lives_NNS unless_IN they_PRP under_IN APB_NNP Opinion_NNP No._NN ._.
25_CD ._.
are_VBP regarded_VBN as_IN having_VBG indefinite_JJ useful_JJ lives_NNS ,_, Software_NNP costs_NNS in_IN which_WDT case_NN they_PRP are_VBP tested_VBN annually_RB for_IN Under_IN UK_NNP GAAP_NNP ,_, AstraZeneca_NNP capitalises_VBZ Statement_NNP of_IN cash_NN flows_NNS :_: Basis_NN of_IN impairment_NN ._.
Goodwill_NNP ,_, arising_VBG on_IN a_DT certain_JJ defined_VBN software_NN costs_NNS ._.
Under_IN US_NNP preparation_NN combination_NN of_IN business_NN ,_, is_VBZ tested_VBN for_IN GAAP_NNP software_NN costs_NNS are_VBP generally_RB AstraZenecas_NNP Statement_NNP of_IN Group_NNP Cash_NNP impairment_NN annually_RB in_IN lieu_NN of_IN amortisation_NN ._.
capitalized_JJ and_CC amortised_JJ over_IN three_CD to_TO five_CD Flow_NN is_VBZ prepared_VBN in_IN accordance_NN with_IN United_NNP SFAS_NNP No._NN ._.
142_CD requires_VBZ that_IN goodwill_NN and_CC years_NNS ._.
Kingdom_NNP Financial_NNP Reporting_NNP Standard_NNP 1_CD intangible_JJ assets_NNS acquired_VBN prior_RB to_TO 1_CD July_NNP 2001_CD Revised_VBN 1996_CD FRS_NNP 1_CD ,_, whose_WP$ objective_NN should_MD continue_VB to_TO be_VB amortised_VBN and_CC tested_VBN Foreign_JJ exchange_NN and_CC principles_NNS are_VBP similar_JJ to_TO those_DT set_VBN out_RP in_IN for_IN impairment_NN until_IN the_DT adoption_NN of_IN the_DT Under_IN UK_NNP GAAP_NNP ,_, unrealised_JJ gains_NNS and_CC losses_NNS SFAS_NNP No._NN ._.
142_CD an_DT on_IN foreign_JJ currency_NN transactions_NNS to_TO hedge_VB The_DT principal_JJ differences_NNS between_IN the_DT impairment_NN test_NN must_MD be_VB carried_VBN out_RP on_IN all_DT anticipated_VBN ,_, but_CC not_RB firmly_RB committed_VBN ,_, foreign_JJ standards_NNS relate_VBP to_TO classification_NN ._.
Under_IN FRS_NNP intangible_JJ assets_NNS with_IN indefinite_JJ useful_JJ lives_NNS currency_NN transactions_NNS may_MD be_VB deferred_VBN and_CC 1_CD ,_, the_DT Company_NN presents_VBZ its_PRP$ cash_NN flows_VBZ for_IN a_DT and_CC goodwill_NN ._.
Any_DT impairment_NN loss_NN identified_VBN accounted_VBD for_IN at_IN the_DT same_JJ time_NN as_IN the_DT operating_NN activities_NNS :_: b_NN dividends_NNS received_VBN on_IN the_DT date_NN of_IN adoption_NN of_IN SFAS_NNP No._NN ._.
Under_IN US_NNP GAAP_NNP from_IN joint_JJ ventures_NNS and_CC associates_NNS :_: c_NN returns_NNS should_MD be_VB accounted_VBN for_IN as_IN a_DT cumulative_JJ such_JJ deferral_NN is_VBZ not_RB permitted_VBN except_IN in_IN on_IN investments_NNS and_CC servicing_NN of_IN finance_NN :_: d_LS effect_NN of_IN a_DT change_NN in_IN accounting_NN principle_NN ._.
tax_NN paid_VBN :_: e_LS capital_NN expenditure_NN and_CC financial_JJ At_IN the_DT same_JJ time_NN ,_, the_DT estimated_VBN useful_JJ lives_NNS investment_NN :_: f_LS acquisitions_NNS and_CC disposals_NNS :_: g_NN of_IN amortised_JJ intangible_JJ assets_NNS must_MD be_VB Derivative_JJ instruments_NNS and_CC hedging_VBG dividends_NNS paid_VBN to_TO shareholders_NNS :_: h_VB reviewed_VBN ._.
activities_NNS management_NN of_IN liquid_JJ resources_NNS :_: and_CC i_FW Under_IN US_NNP GAAP_NNP ,_, all_DT derivative_JJ instruments_NNS financing_NN ._.
95_CD requires_VBZ only_RB three_CD Adoption_NN of_IN these_DT new_JJ accounting_NN standards_NNS should_MD be_VB recognized_VBN as_IN assets_NNS or_CC liabilities_NNS in_IN categories_NNS of_IN cash_NN flow_NN activity_NN being_VBG a_DT has_VBZ resulted_VBN in_IN an_DT estimated_VBN increase_NN in_IN net_JJ the_DT balance_NN sheet_NN at_IN fair_JJ value_NN ._.
Gains_NNS and_CC operating_NN :_: b_NN investing_NN :_: and_CC c_NN financing_NN ._.
income_NN of_IN $_$ 755m_CD including_VBG amortisation_NN losses_NNS are_VBP recognized_VBN in_IN net_JJ income_NN unless_IN charged_VBN under_IN UK_NNP GAAP_NNP of_IN $_$ 55m_CD ._.
Initial_JJ they_PRP are_VBP regarded_VBN as_IN hedges_NNS ._.
Under_IN UK_NNP Cash_NNP flows_VBZ from_IN taxation_NN ,_, returns_NNS on_IN adoption_NN of_IN SFAS_NNP No._NN ._.
142_CD did_VBD not_RB result_VB in_IN an_DT GAAP_NNP ,_, these_DT instruments_NNS are_VBP measured_VBN at_IN investments_NNS and_CC servicing_NN of_IN finance_NN and_CC impairment_NN charge_NN ,_, nor_CC was_VBD there_EX any_DT cost_NN and_CC gains_NNS or_CC losses_NNS deferred_VBN until_IN the_DT dividends_NNS received_VBD from_IN joint_JJ ventures_NNS and_CC impairment_NN at_IN the_DT subsequent_JJ annual_JJ test_NN ._.
associates_NNS under_IN FRS_NNP 1_CD would_MD be_VB included_VBN as_IN Had_VBD goodwill_NN not_RB been_VBN amortised_VBN in_IN 2001_CD ,_, net_JJ operating_NN activities_NNS under_IN SFAS_NNP No._NN ._.
95_CD :_: income_NN would_MD have_VB increased_VBN from_IN $_$ 1,397_CD m_NN Deferred_JJ income_NN capital_NN expenditure_NN and_CC financial_JJ investment_NN to_TO $_$ 2,125_CD m_NN 2000_CD $_$ 865m_CD to_TO $_$ 1,716_CD m_NN with_IN a_DT Under_IN UK_NNP GAAP_NNP ,_, profits_NNS or_CC losses_NNS from_IN the_DT and_CC acquisitions_NNS and_CC disposals_NNS would_MD be_VB corresponding_JJ increase_NN in_IN basic_JJ and_CC diluted_JJ sale_NN of_IN product_NN related_VBN intangible_JJ assets_NNS are_VBP included_VBN as_IN investing_VBG activities_NNS :_: and_CC earnings_NNS per_IN share_NN from_IN $_$ 0.77_CD to_TO $_$ 1.21_CD 2000_CD classified_VBN in_IN other_JJ operating_NN income_NN and_CC are_VBP distributions_NNS would_MD be_VB included_VBN as_IN a_DT financing_NN $_$ 0.49_CD to_TO $_$ 0.97_CD ._.
No_DT changes_NNS were_VBD made_VBN to_TO stated_VBN after_IN taking_VBG account_NN of_IN product_NN activity_NN under_IN SFAS_NNP No._NN ._.
Under_IN FRS_NNP 1_CD estimated_VBD useful_JJ lives_NNS of_IN intangible_JJ assets_NNS ._.
disposal_NN costs_NNS and_CC costs_NNS of_IN minor_JJ cash_NN comprises_VBZ cash_NN in_IN hand_NN and_CC deposits_NNS outstanding_JJ obligations_NNS ._.
Under_IN US_NNP GAAP_NNP ,_, repayable_JJ on_IN demand_NN ,_, less_JJR overdrafts_NNS SFAS_NNP No._NN ._.
144_CD Accounting_NN for_IN the_DT such_JJ profits_NNS are_VBP deferred_VBN and_CC recognized_VBN in_IN repayable_JJ on_IN demand_NN :_: and_CC liquid_JJ resources_NNS Impairment_NN or_CC Disposal_NN of_IN Long-Lived_NNP Assets_NNPS AstraZeneca_NNP Annual_JJ Report_NNP and_CC Form_NN 20-F_JJ 2002_CD Additional_JJ Information_NN for_IN US_NNP Investors_NNPS www_NN ._.
com_NN 115_CD addresses_NNS financial_JJ accounting_NN and_CC reporting_VBG for_IN the_DT impairment_NN or_CC disposal_NN of_IN long-lived_JJ assets_NNS and_CC supersedes_NNS SFAS_NNP No._NN ._.
121_CD ,_, Accounting_NNP for_IN the_DT Impairment_NN of_IN Long-Lived_NNP Assets_NNPS and_CC for_IN Long-Lived_NNP Assets_NNPS to_TO be_VB Disposed_VBN of_IN and_CC the_DT accounting_NN and_CC reporting_NN provisions_NNS of_IN APB_NNP Opinion_NNP No._NN ._.
30_CD ,_, Reporting_NNP the_DT Results_NNS of_IN Operations_NNP Reporting_NNP the_DT Effects_NNPS of_IN Disposal_NNP of_IN a_DT Segment_NN of_IN a_DT Business_NN ,_, and_CC Extraordinary_JJ ,_, Unusual_JJ and_CC Infrequently_NNP Occurring_NNP Events_NNS and_CC Transactions_NNS ,_, for_IN the_DT disposal_NN of_IN a_DT segment_NN of_IN a_DT business_NN ._.
It_PRP is_VBZ effective_JJ for_IN accounting_NN periods_NNS beginning_VBG on_IN or_CC after_IN 15_CD December_NNP 2001_CD ._.
144_CD did_VBD not_RB have_VB a_DT material_NN effect_NN ._.
New_NNP accounting_NN standards_NNS not_RB yet_RB adopted_VBN SFAS_NNP No._NN ._.
143_CD Accounting_NN for_IN Asset_NNP Retirement_NNP Obligation_NNP addresses_VBZ the_DT accounting_NN and_CC reporting_VBG for_IN obligations_NNS associated_VBN with_IN the_DT retirement_NN of_IN long-lived_JJ assets_NNS and_CC the_DT associated_VBN asset_NN retirement_NN costs_NNS ._.
It_PRP is_VBZ effective_JJ for_IN accounting_NN periods_NNS beginning_VBG on_IN or_CC after_IN 15_CD June_NNP 2002_CD ._.
143_CD is_VBZ not_RB expected_VBN to_TO have_VB a_DT material_NN effect_NN ._.
146_CD Accounting_NN for_IN Costs_NNS Associated_NNP with_IN Exit_NN or_CC Disposal_NNP Activities_NNPS ,_, issued_VBN on_IN 30_CD July_NNP 2002_CD requires_VBZ costs_NNS associated_VBN with_IN exit_NN or_CC disposal_NN activities_NNS to_TO be_VB recognized_VBN when_WRB the_DT costs_NNS are_VBP incurred_VBN rather_RB than_IN at_IN the_DT date_NN of_IN commitment_NN to_TO an_DT exit_NN or_CC disposal_NN plan_NN ._.
The_DT provisions_NNS are_VBP effective_JJ for_IN disposals_NNS initialised_VBN after_IN 31_CD December_NNP 2002_CD and_CC restatement_NN of_IN prior_JJ periods_NNS is_VBZ not_RB required_VBN ._.
146_CD may_MD apply_VB to_TO future_JJ activities_NNS which_WDT are_VBP not_RB currently_RB envisaged_VBN it_PRP is_VBZ not_RB possible_JJ to_TO assess_VB the_DT impact_NN of_IN SFAS_NNP No._NN ._.
148_CD Accounting_NN for_IN Stock_NNP Based_VBD Compensation_NNP Transition_NN and_CC Disclosure_NN an_DT amendment_NN of_IN FASB_NNP Statement_NNP No._NN ._.
123_CD permits_VBZ two_CD additional_JJ transition_NN methods_NNS for_IN entities_NNS that_WDT adopt_VBP the_DT fair_JJ value_NN based_VBN method_NN of_IN accounting_NN for_IN stock-based_JJ employee_NN compensation_NN ._.
The_DT Statement_NN also_RB requires_VBZ new_JJ disclosures_NNS about_IN the_DT ramp-up_JJ effect_NN of_IN stock-based_JJ employee_NN compensation_NN on_IN reported_VBN results_NNS and_CC that_IN those_DT effects_NNS be_VB disclosed_VBN more_RBR prominently_RB by_IN specifying_VBG the_DT form_NN ,_, content_NN and_CC location_NN of_IN those_DT disclosures_NNS ._.
The_DT transition_NN guidance_NN and_CC annual_JJ disclosure_NN provisions_NNS of_IN SFAS_NNP No._NN ._.
148_CD are_VBP effective_JJ for_IN fiscal_JJ years_NNS ending_VBG after_IN 15_CD December_NNP 2002_CD ._.
AstraZeneca_NNP has_VBZ not_RB yet_RB determined_VBN whether_IN it_PRP will_MD adopt_VB the_DT transition_NN provisions_NNS of_IN SFAS_NNP No._NN ._.
com_NN 116_CD Additional_JJ Information_NN for_IN US_NNP Investors_NNPS continued_VBD Differences_NNS between_IN UK_NNP and_CC US_NNP accounting_NN principles_NNS continued_VBD Introduction_NNP As_IN a_DT result_NN of_IN the_DT significant_JJ difference_NN between_IN the_DT UK_NNP GAAP_NNP and_CC US_NNP GAAP_NNP treatment_NN of_IN the_DT combination_NN of_IN Astra_NNP and_CC Zeneca_NNP in_IN the_DT year_NN of_IN acquisition_NN ,_, and_CC in_IN the_DT results_NNS of_IN preceding_VBG periods_NNS ,_, condensed_JJ statements_NNS of_IN operations_NNS and_CC cash_NN flow_NN under_IN US_NNP GAAP_NNP have_VBP been_VBN prepared_VBN for_IN the_DT benefit_NN of_IN US_NNP investors_NNS ._.
The_DT following_NN is_VBZ a_DT summary_NN of_IN the_DT material_NN adjustments_NNS to_TO net_JJ income_NN and_CC shareholders_NNS equity_NN which_WDT would_MD have_VB been_VBN required_VBN if_IN US_NNP GAAP_NNP had_VBD been_VBN applied_VBN instead_RB of_IN UK_NNP GAAP_NNP ._.
As_IN noted_VBN on_IN page_NN 62_CD ,_, 2001_CD and_CC 2000_CD net_JJ income_NN and_CC shareholders_NNS equity_NN under_IN UK_NNP GAAP_NNP have_VBP been_VBN restated_VBN under_IN FRS19_NNP Deferred_NNP Tax_NNP ._.
On_IN this_DT basis_NN the_DT deferred_JJ tax_NN adjustment_NN below_IN as_RB been_VBN restated_VBN for_IN those_DT years_NNS ._.
Net_JJ income_NN 2002 2001 2000_CD $_$ m_CD $_$ m_CD $_$ m_CD Net_JJ income_NN ,_, as_IN shown_VBN in_IN the_DT consolidated_JJ statements_NNS of_IN income_NN before_IN exceptional_JJ items_NNS restated_VBN 3,186_CD 3,044_CD 2,858_CD Exceptional_JJ items_NNS after_IN tax_NN 350 138 581_CD Net_JJ income_NN for_IN the_DT period_NN under_IN UK_NNP GAAP_NNP restated_VBD 2,836_CD 2,906_CD 2,277_CD Adjustments_NNS to_TO conform_VB to_TO US_NNP GAAP_NNP Purchase_NN accounting_NN adjustments_NNS including_VBG goodwill_NN and_CC intangibles_VBZ Deemed_JJ acquisition_NN of_IN Astra_NNP Amortisation_NNP and_CC other_JJ acquisition_NN adjustments_NNS 864_CD 1,514_CD 1,756_CD Others_NNS 55_CD 20_CD Capitalisation_NNP ,_, less_JJR disposals_NNS and_CC amortisation_NN of_IN interest_NN 46_CD 57_CD 45_CD Deferred_JJ taxation_NN On_IN fair_JJ values_NNS of_IN Astra_NNP 239 249 284_CD Others_NNS restated_VBN 99 198 115_CD Pension_NN expense_NN 50_CD 33_CD 50_CD Post-retirement_NN benefits_NNS plan_VBP amendment_NN 4_CD 44_CD Software_NNP costs_NNS 46_CD 10_CD 98_CD Restructuring_NN costs_NNS 22_CD 97_CD Share_NN based_VBN compensation_NN 33_CD 7_CD 33_CD Fair_NNP value_NN of_IN derivative_JJ financial_JJ instruments_NNS 93_CD 18_CD Deferred_JJ income_NN recognition_NN 61_CD 75_CD Unrealised_JJ losses_NNS on_IN foreign_JJ exchange_NN and_CC others_NNS 1_CD 10_CD 2_CD Net_JJ income_NN before_IN cumulative_JJ effect_NN of_IN change_NN in_IN accounting_NN policy_NN 2,307_CD 1,365_CD 865_CD Cumulative_JJ effect_NN of_IN change_NN in_IN accounting_NN policy_NN ,_, net_NN of_IN tax_NN ,_, on_IN adoption_NN of_IN SFAS_NNP No_NNP 133_CD 32_CD Net_JJ income_NN in_IN accordance_NN with_IN US_NNP GAAP_NNP 2,307_CD 1,397_CD 865_CD AstraZeneca_NNP Annual_JJ Report_NNP and_CC Form_NN 20-F_JJ 2002_CD Additional_JJ Information_NN for_IN US_NNP Investors_NNPS www_NN ._.
com_NN 117_CD Differences_NNS between_IN UK_NNP and_CC US_NNP accounting_NN principles_NNS continued_VBD US_NNP GAAP_NNP Condensed_NNP Consolidated_NNP Statement_NNP of_IN Operations_NNP 2002 2001 2000_CD For_IN the_DT years_NNS ended_VBN 31_CD December_NNP $_$ m_CD $_$ m_CD $_$ m_CD Sales_NNS 17,841_CD 16,222_CD 15,583_CD Cost_NN of_IN sales_NNS 4,520_CD 4,198_CD 3,960_CD Distribution_NN costs_NNS 141 122 210_CD Research_NNP and_CC development_NN 3,069_CD 2,687_CD 2,620_CD Selling_NNP ,_, general_JJ and_CC administrative_JJ expenses_NNS 6,165_CD 5,219_CD 4,861_CD Acquisition_NNP related_VBN costs_NNS 224_CD 419_CD Amortisation_NNP of_IN intangibles_NNS and_CC goodwill_NN 1,052_CD 1,769_CD 2,043_CD Other_JJ income_NN 308 283 223_CD Operating_NN income_NN 3,202_CD 2,286_CD 1,693_CD Net_JJ interest_NN income_NN 140 188 183_CD Income_NN from_IN continuing_VBG operations_NNS before_IN taxation_NN 3,342_CD 2,474_CD 1,876_CD Taxes_NNS on_IN income_NN from_IN continuing_VBG operations_NNS 1,035_CD 1,109_CD 969_CD Net_JJ income_NN from_IN continuing_VBG operations_NNS 2,307_CD 1,365_CD 907_CD Discontinued_VBN operations_NNS :_: Net_JJ income_NN from_IN discontinued_VBN operations_NNS 42_CD Net_JJ income_NN before_IN cumulative_JJ effect_NN of_IN change_NN in_IN accounting_NN policy_NN 2,307_CD 1,365_CD 865_CD Cumulative_JJ effect_NN of_IN change_NN in_IN accounting_NN policy_NN on_IN adoption_NN of_IN SFAS_NNP No_NNP 133_CD 32_CD Net_JJ income_NN for_IN the_DT year_NN 2,307_CD 1,397_CD 865_CD Weighted_JJ average_JJ number_NN of_IN $_$ 0.25_CD Ordinary_NNP Shares_NNP in_IN issue_NN millions_NNS of_IN shares_NNS 1,733_CD 1,758_CD 1,768_CD Dilutive_JJ impact_NN of_IN share_NN options_NNS outstanding_JJ millions_NNS of_IN shares_NNS 2_CD 32_CD Diluted_VBN weighted_JJ average_JJ number_NN of_IN $_$ 0.25_CD Ordinary_NNP Shares_NNP in_IN accordance_NN with_IN US_NNP GAAP_NNP millions_NNS of_IN shares_NNS 1,735_CD 1,761_CD 1,770_CD Net_JJ income_NN per_IN $_$ 0.25_CD Ordinary_NNP Share_NN and_CC ADS_NNPS before_IN change_NN in_IN accounting_NN policy_NN in_IN accordance_NN with_IN US_NNP GAAP_NNP basic_JJ and_CC diluted_JJ $_$ $_$ 1.33_CD $_$ 0.77_CD $_$ 0.49_CD Net_JJ income_NN per_IN $_$ 0.25_CD Ordinary_NNP Share_NN and_CC ADS_NNPS after_IN change_NN in_IN accounting_NN policy_NN in_IN accordance_NN with_IN US_NNP GAAP_NNP basic_JJ and_CC diluted_JJ $_$ $_$ 1.33_CD $_$ 0.79_CD $_$ 0.49_CD 2002 2001 2000_CD Net_JJ income_NN from_IN continuing_VBG operations_NNS per_IN $_$ 0.25_CD Ordinary_NNP Share_NN and_CC ADS_NNPS in_IN accordance_NN with_IN US_NNP GAAP_NNP basic_JJ and_CC diluted_JJ $_$ $_$ 1.33_CD $_$ 0.79_CD $_$ 0.51_CD Net_JJ loss_NN from_IN discontinued_VBN operations_NNS per_IN $_$ 0.25_CD Ordinary_NNP Share_NN and_CC ADS_NNPS in_IN accordance_NN with_IN US_NNP GAAP_NNP basic_JJ and_CC diluted_JJ $_$ $_$ 0.02_CD The_DT dividend_NN in_IN specie_NN in_IN 2000_CD in_IN respect_NN of_IN the_DT demerger_NN of_IN Zeneca_NNP Agrochemicals_NNPS under_IN US_NNP GAAP_NNP amounted_VBD to_TO $_$ 836m_CD ,_, after_IN realized_VBN exchange_NN gains_NNS on_IN the_DT translation_NN of_IN foreign_JJ currency_NN financial_JJ statements_NNS of_IN $_$ 297m_CD ._.
As_IN noted_VBN on_IN page_NN 62_CD ,_, cash_NN settlement_NN discounts_NNS have_VBP been_VBN reclassified_VBN from_IN cost_NN of_IN sales_NNS to_TO sales_NNS ._.
Comparative_JJ information_NN for_IN 2001_CD and_CC 2000_CD has_VBZ also_RB been_VBN reclassified_VBN for_IN consistency_NN of_IN presentation_NN ._.
com_NN 118_CD Additional_JJ Information_NN for_IN US_NNP Investors_NNPS continued_VBD Differences_NNS between_IN UK_NNP and_CC US_NNP accounting_NN principles_NNS continued_VBD US_NNP GAAP_NNP Statement_NN of_IN Comprehensive_NNP Income_NNP 2002 2001 2000_CD For_IN the_DT years_NNS ended_VBN 31_CD December_NNP $_$ m_CD $_$ m_CD $_$ m_CD Net_JJ income_NN for_IN the_DT year_NN 2,307_CD 1,397_CD 865_CD Exchange_NNP gains_NNS losses_NNS net_NN of_IN tax_NN 2,919_CD 1,473_CD 2,184_CD Exchange_NNP realized_VBD on_IN demerger_NN of_IN Zeneca_NNP Agrochemicals_NNPS 297_CD Other_JJ movements_NNS 73_CD 2_CD Total_JJ Comprehensive_NNP Income_NNP 5,153_CD 76_CD 1,618_CD Other_JJ movements_NNS in_IN 2002_CD include_VBP the_DT recognition_NN of_IN a_DT minimum_JJ liability_NN under_IN SFAS_NNP 87_CD of_IN $_$ 45m_CD ._.
The_DT cumulative_JJ exchange_NN gains_NNS and_CC losses_NNS net_NN of_IN tax_NN on_IN the_DT translation_NN of_IN foreign_JJ currency_NN financial_JJ statements_NNS under_IN US_NNP GAAP_NNP are_VBP set_VBN out_RP in_IN the_DT following_JJ note_NN :_: 2002 2001 2000_CD For_IN the_DT years_NNS ended_VBN 31_CD December_NNP $_$ m_CD $_$ m_CD $_$ m_CD Balance_NN at_IN 1_CD January_NNP 4,318_CD 2,845_CD 364_CD Movement_NNP in_IN year_NN 2,919_CD 1,473_CD 2,481_CD Balance_NN at_IN 31_CD December_NNP 1,399_CD 4,318_CD 2,845_CD Stock_NNP compensation_NN In_IN the_DT Groups_NNS financial_JJ statements_NNS prepared_VBN under_IN UK_NNP GAAP_NNP ,_, no_DT cost_NN is_VBZ accrued_VBN for_IN the_DT share_NN options_NNS awarded_VBN to_TO employees_NNS under_IN the_DT Zeneca_NNP 1994_CD Executive_NNP Share_NNP Option_NN Scheme_NN ,_, the_DT AstraZeneca_NNP Share_NN Option_NN Plan_NN ,_, and_CC the_DT AstraZeneca_NNP Savings-Related_NNP Share_NNP Option_NN Scheme_NN as_IN the_DT exercise_NN price_NN is_VBZ equivalent_JJ to_TO the_DT market_NN value_NN at_IN the_DT date_NN of_IN grant_NN ._.
Under_IN US_NNP GAAP_NNP the_DT cost_NN is_VBZ calculated_VBN as_IN the_DT difference_NN between_IN the_DT option_NN price_NN and_CC the_DT market_NN price_NN at_IN the_DT date_NN of_IN grant_NN or_CC ,_, for_IN variable_JJ plans_NNS ,_, at_IN the_DT end_NN of_IN the_DT reporting_NN period_NN until_IN measurement_NN date_NN ._.
Under_IN the_DT requirements_NNS of_IN APB_NNP Opinion_NNP No._NN ._.
25_CD any_DT compensation_NN cost_NN would_MD be_VB amortised_VBN over_IN the_DT period_NN from_IN the_DT date_NN the_DT options_NNS are_VBP granted_VBN to_TO the_DT date_NN they_PRP are_VBP first_JJ exercisable_JJ ._.
Under_IN US_NNP GAAP_NNP in_IN the_DT net_JJ income_NN reconciliation_NN ,_, the_DT Group_NNP has_VBZ adjusted_VBN for_IN stock_NN compensation_NN costs_NNS as_IN calculated_VBN under_IN APB_NNP Opinion_NNP No_NNP 25_CD ,_, SFAS_NNP No._NN ._.
123_CD sets_NNS out_IN an_DT alternative_JJ methodology_NN for_IN recognizing_VBG the_DT compensation_NN cost_NN based_VBN on_IN the_DT fair_JJ value_NN at_IN grant_NN date_NN ._.
Had_VBD the_DT Group_NNP adopted_VBD this_DT methodology_NN ,_, the_DT incremental_JJ effect_NN on_IN net_JJ income_NN under_IN US_NNP GAAP_NNP is_VBZ shown_VBN below_IN :_: 2002 2001 2000_CD $_$ m_CD $_$ m_CD $_$ m_CD Net_JJ income_NN under_IN US_NNP GAAP_NNP as_IN reported_VBN 2,307_CD 1,397_CD 865_CD Compensation_NNP cost_NN after_IN adjusting_VBG for_IN APB_NNP 25_CD credit_NN of_IN $_$ 33m_CD 155_CD 76_CD 46_CD Pro_FW forma_FW net_JJ income_NN 2,152_CD 1,321_CD 819_CD Pro_FW forma_FW net_JJ income_NN per_IN $_$ 0.25_CD Ordinary_NNP Share_NN and_CC ADS_NNPS in_IN accordance_NN with_IN US_NNP GAAP_NNP basic_JJ and_CC diluted_VBN :_: As_IN reported_VBN $_$ $_$ 1.33_CD $_$ 0.79_CD $_$ 0.49_CD Pro_FW forma_FW $_$ $_$ 1.24_CD $_$ 0.75_CD $_$ 0.46_CD The_DT fair_JJ value_NN of_IN options_NNS granted_VBN is_VBZ estimated_VBN ,_, based_VBN on_IN the_DT stock_NN price_NN at_IN the_DT grant_NN date_NN ,_, using_VBG the_DT Black-Scholes_NNP option_NN pricing_NN model_NN with_IN the_DT following_VBG assumptions_NNS :_: 2002 2001 2000_CD Dividend_NN yield_NN 1.6_CD %_NN 1.5_CD %_NN 2.0_CD %_NN Expected_VBN volatility_NN 30.0_CD %_NN 20.0_CD %_NN 20.0_CD %_NN Risk-free_JJ interest_NN rate_NN 5.2_CD %_NN 4.2_CD %_NN 5.9_CD %_NN Expected_VBN lives_NNS :_: 1994_CD Scheme_NNP 6.0_CD years_NNS Expected_VBN lives_NNS :_: AstraZeneca_NNP Share_NNP Option_NN Plan_NN 6.0_CD years_NNS 6.0_CD years_NNS 6.0_CD years_NNS Expected_VBN lives_NNS :_: SAYE_NNP Scheme_NNP 4.3_CD years_NNS 4.3_CD years_NNS 4.6_CD years_NNS In_IN the_DT initial_JJ phase-in_JJ period_NN ,_, the_DT effects_NNS of_IN applying_VBG SFAS_NNP No._NN ._.
123_CD for_IN disclosing_VBG compensation_NN cost_NN may_MD not_RB be_VB representative_NN of_IN the_DT effects_NNS on_IN pro_FW forma_FW net_JJ income_NN and_CC earnings_NNS per_IN share_NN for_IN future_JJ years_NNS ._.
com_NN 119_CD Differences_NNS between_IN UK_NNP and_CC US_NNP accounting_NN principles_NNS continued_VBD Pension_NN and_CC post-retirement_NN benefits_NNS For_IN the_DT purposes_NNS of_IN US_NNP GAAP_NNP ,_, the_DT pension_NN costs_NNS of_IN the_DT major_JJ UK_NNP retirement_NN plan_NN and_CC of_IN the_DT retirement_NN plans_NNS of_IN the_DT major_JJ non-UK_JJ subsidiaries_NNS have_VBP been_VBN restated_VBN in_IN the_DT following_VBG tables_NNS in_IN accordance_NN with_IN the_DT requirements_NNS of_IN SFAS_NNP No._NN ._.
These_DT plans_NNS comprise_VBP a_DT substantial_JJ portion_NN of_IN the_DT actuarial_JJ liabilities_NNS of_IN all_DT AstraZeneca_NNP retirement_NN plans_NNS ._.
The_DT changes_NNS in_IN projected_VBN benefit_NN obligations_NNS ,_, plan_NN assets_NNS and_CC details_NNS of_IN the_DT funded_JJ status_NN of_IN these_DT retirement_NN plans_NNS ,_, together_RB with_IN the_DT changes_NNS in_IN the_DT accumulated_VBN other_JJ post-retirement_JJ benefit_NN obligations_NNS ,_, under_IN SFAS_NNP No._NN ._.
132_CD are_VBP as_IN follows_VBZ :_: Other_JJ post-retirement_JJ Pension_NN benefits_NNS benefits_NNS Change_NNP in_IN projected_VBN benefit_NN obligation_NN 2002 2001 2002 2001_CD $_$ m_CD $_$ m_CD $_$ m_CD $_$ m_CD Benefit_NNP obligation_NN at_IN beginning_NN of_IN year_NN 4,337_CD 4,188_CD 205_CD 197_CD Service_NNP cost_NN 114_CD 102_CD 8_CD 7_CD Interest_NN cost_NN 263_CD 243_CD 14_CD 14_CD Participant_NN contributions_NNS 18_CD 17_CD Plan_NNP amendments_NNS 11_CD Actuarial_JJ gain_NN loss_NN 80_CD 75_CD 23_CD 1_CD Special_JJ termination_NN benefits_NNS 12_CD 19_CD Settlement_NNP and_CC curtailment_NN 24_CD Benefits_NNPS paid_VBD 206_CD 198_CD 19_CD 14_CD Exchange_NNP 408_CD 98_CD 3_CD 2_CD Benefit_NNP obligation_NN at_IN end_NN of_IN year_NN 5,026_CD 4,337_CD 210_CD 205_CD Other_JJ post-retirement_NN Pension_NN benefits_NNS benefits_NNS Change_NNP in_IN plan_NN assets_NNS 2002 2001 2002 2001_CD $_$ m_CD $_$ m_CD $_$ m_CD $_$ m_CD Fair_NN value_NN at_IN 1_CD January_NNP 3,753_CD 3,803_CD Actual_JJ return_NN on_IN plan_NN assets_NNS 142_CD 45_CD 16_CD Group_NNP contribution_NN 284 170 161_CD Participant_NN contributions_NNS 18_CD 17_CD Settlement_NNP and_CC curtailment_NN Benefits_NNS paid_VBD 205_CD 198_CD 12_CD Exchange_NNP 330_CD 84_CD Fair_NNP value_NN of_IN plan_NN assets_NNS at_IN end_NN of_IN year_NN 4,038_CD 3,753_CD 133_CD Funded_VBN status_NN of_IN plans_NNS 988_CD 584_CD 77_CD 205_CD Unrecognised_JJ net_JJ loss_NN profit_NN 938_CD 396_CD Prior_RB service_NN cost_NN not_RB recognized_VBN 29_CD 35_CD Unrecognised_JJ net_JJ obligation_NN on_IN implementation_NN 3_CD 6_CD 18_CD 147_CD 77_CD 205_CD Adjustments_NNS to_TO recognize_VB minimum_JJ liability_NN Intangible_JJ assets_NNS 45_CD Accumulated_VBN other_JJ comprehensive_JJ income_NN 45_CD Accrued_VBN benefit_NN liability_NN 108_CD 147_CD 77_CD 205_CD AstraZeneca_NNP Annual_JJ Report_NNP and_CC Form_NN 20-F_JJ 2002_CD Additional_JJ Information_NN for_IN US_NNP Investors_NNPS www_NN ._.
com_NN 120_CD Additional_JJ Information_NN for_IN US_NNP Investors_NNPS continued_VBD Differences_NNS between_IN UK_NNP and_CC US_NNP accounting_NN principles_NNS continued_VBD At_IN 31_CD December_NNP 2002_CD ,_, the_DT projected_VBN benefit_NN obligation_NN ,_, accumulated_VBN benefit_NN obligation_NN and_CC fair_JJ value_NN of_IN the_DT plan_NN assets_NNS in_IN respect_NN of_IN the_DT retirement_NN plans_NNS above_IN with_IN accumulated_VBN benefit_NN obligations_NNS in_IN excess_NN of_IN plan_NN assets_NNS were_VBD $_$ 4,249_CD m_NN ,_, $_$ 3,557_CD m_NN and_CC $_$ 3,296_CD m_NN ,_, 2001_CD $_$ 97m_CD ,_, $_$ 73m_CD and_CC $_$ nil_JJ respectively_RB ._.
Assumed_VBN discount_NN rates_NNS and_CC rates_NNS of_IN increase_NN in_IN remuneration_NN used_VBN in_IN calculating_VBG the_DT projected_VBN benefit_NN obligations_NNS together_RB with_IN long_JJ term_NN rates_NNS of_IN return_NN on_IN plan_NN assets_NNS vary_VBP according_VBG to_TO the_DT economic_JJ conditions_NNS of_IN the_DT country_NN in_IN which_WDT the_DT retirement_NN plans_NNS are_VBP situated_VBN ._.
The_DT weighted_JJ average_NN rates_NNS used_VBN for_IN calculation_NN of_IN year_NN end_NN benefit_NN obligations_NNS and_CC forecast_NN benefit_NN cost_NN in_IN the_DT main_JJ retirement_NN plans_NNS and_CC other_JJ benefit_NN obligations_NNS for_IN SFAS_NNP No._NN ._.
132_CD purposes_NNS were_VBD as_IN follows_VBZ :_: Pension_NN benefits_NNS Other_JJ post-retirement_NN benefits_NNS 2002 2001 2000 2002_CD 2001_CD 2000_CD %_NN %_NN %_NN %_NN %_NN %_NN Discount_NNP rate_NN 5.8_CD 6.0_CD 5.6_CD 6.6_CD 7.1_CD 7.1_CD Long_JJ term_NN rate_NN of_IN increase_NN in_IN remuneration_NN 4.1_CD 4.4_CD 4.4_CD 4.8_CD n_VBD a_DT n_NN a_DT Expected_VBN long_JJ term_NN return_NN on_IN assets_NNS 6.4_CD 6.5_CD 6.2_CD 7.8_CD n_VBD a_DT n_NN a_DT The_DT Group_NNP has_VBZ assumed_VBN a_DT long_JJ term_NN rate_NN of_IN increase_NN in_IN healthcare_NN costs_NNS of_IN 11.0_CD %_NN ,_, reducing_VBG to_TO 5.0_CD %_NN ._.
Pension_NN benefits_NNS Other_JJ post-retirement_NN benefits_NNS 2002 2001 2000 2002_CD 2001_CD 2000_CD $_$ m_CD $_$ m_CD $_$ m_CD $_$ m_CD $_$ m_CD $_$ m_CD Net_JJ periodic_JJ cost_NN Service_NNP cost_NN present_JJ value_NN of_IN benefits_NNS accruing_VBG during_IN the_DT year_NN 114 102 152_CD 8_CD 710_CD Interest_NN cost_NN on_IN projected_VBN benefit_NN obligations_NNS 263 243 301_CD 14_CD 14_CD 17_CD Expected_VBN return_NN on_IN assets_NNS 263 242 322_CD Net_JJ amortisation_NN and_CC deferral_JJ 28_CD 39_CD 46_CD 1_CD 2_CD 1_CD Net_JJ periodic_JJ cost_NN for_IN the_DT year_NN 142 142 177_CD 21_CD 19_CD 26_CD It_PRP is_VBZ estimated_VBN that_IN a_DT 1_CD percentage_NN point_NN change_NN in_IN the_DT weighted_JJ average_JJ healthcare_NN costs_NNS trend_NN would_MD have_VB the_DT following_JJ effects_NNS on_IN the_DT accumulated_VBN benefit_NN obligation_NN and_CC net_JJ periodic_JJ cost_NN at_IN 31_CD December_NNP 2002_CD :_: 1_CD percentage_NN point_NN increase_NN decrease_NN $_$ m_CD $_$ m_CD Accumulated_VBN benefit_NN obligation_NN 10_CD 9_CD Net_NN periodic_JJ cost_NN 2_CD 1_CD Taxation_NNP 2002 2001 2000_CD Years_NNS ended_VBD 31_CD December_NNP $_$ m_CD $_$ m_CD $_$ m_CD Taxes_NNS on_IN income_NN from_IN continuing_VBG operations_NNS UK_NNP taxation_NN Corporation_NNP tax_NN 165_CD 147_CD 79_CD Double_RB taxation_NN relief_NN 7_CD 4_CD 42_CD Deferred_VBN 40_CD 10_CD 27_CD Overseas_JJ taxation_NN Overseas_JJ taxes_NNS 921 831 956_CD Deferred_JJ taxation_NN 84_CD 125_CD Share_NN of_IN taxation_NN of_IN joint_JJ ventures_NNS and_CC associates_NNS 3_CD Taxes_NNS on_IN income_NN from_IN continuing_VBG operations_NNS 1,035_CD 1,109_CD 969_CD AstraZeneca_NNP Annual_JJ Report_NNP and_CC Form_NN 20-F_JJ 2002_CD Additional_JJ Information_NN for_IN US_NNP Investors_NNPS www_NN ._.
com_NN 121_CD Differences_NNS between_IN UK_NNP and_CC US_NNP accounting_NN principles_NNS continued_VBD The_DT table_NN below_IN reconciles_NNS the_DT UK_NNP statutory_JJ tax_NN charge_NN to_TO the_DT Groups_NNS actual_JJ charge_NN on_IN income_NN from_IN continuing_VBG operations_NNS ._.
2002 2001 2000_CD Years_NNS ended_VBD 31_CD December_NNP $_$ m_CD $_$ m_CD $_$ m_CD Income_NN on_IN continuing_VBG operations_NNS 3,342_CD 2,506_CD 1,876_CD Taxation_NNP charge_NN at_IN UK_NNP corporation_NN tax_NN rate_NN of_IN 30_CD %_NN for_IN 2002_CD 30_CD %_NN for_IN 2001_CD ,_, 30_CD %_NN for_IN 2000_CD 1,002_CD 751_CD 563_CD Acquisition_NNP related_VBN items_NNS 429_CD Goodwill_NNP ,_, Advanta_NNP ,_, and_CC Salick_NNP Health_NNP Care_NNP impairment_NN 190_CD 576_CD Net_JJ effect_NN of_IN different_JJ rates_NNS and_CC eligible_JJ costs_NNS in_IN other_JJ jurisdictions_NNS 21_CD 43_CD 86_CD Exceptional_JJ items_NNS 105_CD 419_CD Other_JJ 51 203 132_CD Tax_NN on_IN income_NN from_IN continuing_VBG operations_NNS 1,035_CD 1,109_CD 969_CD In_IN 2002_CD ,_, claims_VBZ amounting_VBG to_TO $_$ 43m_CD 2001_CD $_$ 109m_CD for_IN tax_NN relief_NN arising_VBG as_IN a_DT result_NN of_IN a_DT restructuring_NN of_IN the_DT AMI_NNP joint_JJ venture_NN in_IN 1998_CD were_VBD made_VBN ._.
Under_IN US_NNP GAAP_NNP ,_, these_DT reliefs_NNS are_VBP adjusted_VBN against_IN the_DT goodwill_NN arising_VBG on_IN the_DT restructuring_NN and_CC included_VBD in_IN other_JJ adjustments_NNS ._.
Shareholders_NNS equity_NN 2002_CD 2001_CD $_$ m_CD $_$ m_CD Total_JJ shareholders_NNS equity_NN under_IN UK_NNP GAAP_NNP restated_VBD 11,172_CD 9,586_CD Adjustments_NNS to_TO conform_VB to_TO US_NNP GAAP_NNP Purchase_NN accounting_NN adjustments_NNS including_VBG goodwill_NN and_CC intangibles_VBZ Deemed_JJ acquisition_NN of_IN Astra_NNP Goodwill_NNP 12,692_CD 11,062_CD Tangible_JJ and_CC intangible_JJ fixed_VBN assets_NNS 7,707_CD 8,139_CD Others_NNS 86_CD 31_CD Capitalisation_NNP ,_, less_JJR disposals_NNS and_CC amortisation_NN of_IN interest_NN 238_CD 192_CD Deferred_JJ taxation_NN On_IN fair_JJ value_NN of_IN Astra_NNP 2,305_CD 2,313_CD Others_NNS restated_VBN 159_CD 68_CD Dividend_NN 808_CD 820_CD Pension_NN expense_NN 271_CD 162_CD Post-retirement_NN benefits_NNS plan_VBP amendment_NN 24_CD 28_CD Software_NNP costs_NNS capitalized_JJ 64_CD 110_CD Fair_NNP value_NN of_IN derivative_JJ financial_JJ instruments_NNS 99_CD 50_CD Deferred_JJ income_NN recognition_NN 14_CD 75_CD Others_NNS 90_CD 58_CD Shareholders_NNS equity_NN in_IN accordance_NN with_IN US_NNP GAAP_NNP 30,183_CD 27,402_CD AstraZeneca_NNP Annual_JJ Report_NNP and_CC Form_NN 20-F_JJ 2002_CD Additional_JJ Information_NN for_IN US_NNP Investors_NNPS www_NN ._.
com_NN 122_CD Additional_JJ Information_NN for_IN US_NNP Investors_NNPS continued_VBD Differences_NNS between_IN UK_NNP and_CC US_NNP accounting_NN principles_NNS continued_VBD US_NNP GAAP_NNP Condensed_NNP Consolidated_NNP Statement_NNP of_IN Cash_NNP Flows_NNP 2002 2001 2000_CD For_IN the_DT years_NNS ended_VBN 31_CD December_NNP $_$ m_CD $_$ m_CD $_$ m_CD Cash_NN flows_VBZ from_IN operating_VBG activities_NNS 4,833_CD 3,126_CD 3,554_CD Cash_NN flows_VBZ from_IN investing_VBG activities_NNS Movement_NNP in_IN short_JJ term_NN investments_NNS and_CC fixed_VBN deposits_NNS 806 260 608_CD New_NNP fixed_JJ asset_NN investments_NNS 1_CD 5_CD 3_CD Disposal_NN of_IN fixed_JJ assets_NNS 66_CD 44_CD 37_CD Acquisitions_NNS and_CC disposals_NNS 44_CD 740_CD Capital_NN expenditure_NN 1,608_CD 1,582_CD 1,460_CD Net_JJ cash_NN outflows_NNS from_IN investing_VBG activities_NNS 2,349_CD 1,327_CD 1,294_CD Net_JJ cash_NN flow_NN before_IN financing_VBG 2,484_CD 1,799_CD 2,260_CD Cash_NN flows_VBZ from_IN financing_VBG activities_NNS Equity_NNP dividends_NNS paid_VBD 1,234_CD 1,236_CD 1,220_CD Repurchase_NN of_IN AstraZeneca_NNP PLC_NNP Ordinary_NNP Shares_NNP 1,154_CD 994_CD 334_CD Net_JJ decrease_NN increase_NN in_IN short_JJ term_NN borrowings_NNS 13_CD 7_CD 67_CD Loans_NNS repaid_VBN new_JJ loans_NNS 105_CD 28_CD 3_CD Repayment_NN of_IN lease_NN finance_NN 2_CD Net_JJ cash_NN outflows_NNS from_IN financing_VBG activities_NNS 2,506_CD 2,195_CD 1,620_CD Decrease_NN increase_NN in_IN cash_NN 22 396 640_CD Cash_NN :_: At_IN 1_CD January_NNP 510 908 262_CD Decrease_NN increase_NN in_IN cash_NN 22 396 640_CD Exchange_NNP movements_NNS 36_CD 2_CD 6_CD At_IN 31_CD December_NNP 524 510 908_CD 1_CD Interest_NN paid_VBN was_VBD $_$ 96m_CD in_IN 2002_CD ,_, $_$ 84m_CD in_IN 2001_CD ,_, $_$ 145m_CD in_IN 2000_CD ._.
